Published in Hepatitis Weekly, April 9th, 2001
Japan and other countries in Asia experience elevated rates of hepatocellular carcinoma (HCC), a primary form of liver cancer, due to the prevalence of hepatitis viruses B and C. Surgical and non-surgical ablative therapies are used for treating second occurrences of liver cancer after primary treatments. However, new research shows second surgeries for cancer recurrence is associated with a lower rate of disease-free survival in patients in Japan.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.